CJC-1295 with DAC vs Tesamorelin

Dose, schedule, route and approval status side by side.

Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.

	CJC-1295 with DAC	Tesamorelin
Status	Not approved	FDA-approved
Also known as	DAC:GRF	Egrifta SV, Egrifta WR
Typical dose	1–2 mg	1.4 mg (SV) or 1.28 mg (WR)
How often	Weekly	Daily
Schedule	Once weekly.	Once daily into the abdomen.
Daily equivalent	≈ 143–286 mcg/day	1.28–1.4 mg/day
Route	Subcutaneous	Subcutaneous
Duration	8–12 weeks reported	Ongoing
Notes	Long-acting form with a half-life of about a week. Clinical development stopped in Phase 2.	Approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. The original formulation was 2 mg daily. The two current formulations are not interchangeable. Calculator values assume a compounded vial.

This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the CJC-1295 with DAC and Tesamorelin pages.

Advertise here